<DOC>
	<DOCNO>NCT00779285</DOCNO>
	<brief_summary>The purpose study evaluate cardiac safety Caelyx patient metastatic breast cancer previously receive chemotherapy anthracyclines .</brief_summary>
	<brief_title>Safety Study CAELYX Patients With Metastatic Breast Cancer Previously Treated With Anthracyclines ( Study P04057 ) ( TERMINATED )</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<criteria>Women histologically cytologically confirm metastatic breast cancer ( prior chemotherapy metastatic disease ) . Prior treatment anthracyclincontaining regimen adjuvant setting ( cumulative dose &gt; 240mg/m^2 &lt; 360mg/m^2 doxorubicin &gt; 430mg/m^2 &lt; 650mg/m^2 epirubicin ) . Women &gt; 18 year age . Documented measurable and/or evaluable metastatic breast cancer appropriate radiological imaging ( compute tomography ( CT ) scan and/or magnetic resonance imaging ( MRI ) ) . Performance status least 60 % ( Karnofsky index ) life expectancy least 12 week . Left ventricular ejection fraction &gt; 50 % . Normal organ function , except abnormal due tumor involvement . Adequate bone marrow function indicate : Platelets &gt; 100,000/mm^3 Hemoglobin &gt; 9 g/dL Neutrophils &gt; 1,500/mm^3 Adequate renal function indicate : Serum Creatinine &lt; 1.5 x upper limit normal Adequate liver function , indicate : Bilirubin aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) &lt; 2 time upper limit normal ( &lt; 4 time upper limit normal related primary disease ) Subjects must capable demonstrate willingness participate study comply procedure sign write informed consent . Women childbearing potential ( include woman less 1 year postmenopausal woman become sexually active ) must use acceptable method birth control ( e.g. , hormonal contraceptive , medically prescribe intrauterine device ( IUD ) , condom combination spermicide ) surgically sterilize ( e.g. , hysterectomy tubal ligation ) . Subjects must understand able adhere dose visit schedule . Patient pregnant breastfeeding . Patients moderate severe heart failure ( New York Heart Association ( NYHA ) class III/IV ) . Hypersensitivity anthracycline therapy history severe hypersensitivity reaction product contain CremophorÂ® EL ( e.g. , cyclosporin injection concentrate teniposide injection concentrate ) . Prior chemotherapy metastatic disease . Clinically significant hepatic disease ( except liver metastasis primary disease ) . Uncontrolled bacterial , viral , fungal infection . Radiotherapy last 4 week prior radiation therapy onethird hemopoietic site . Any currently know malignancy premalignant lesion history malignancy within past five year ( except nonmelanoma skin cancer surgically cure cervical cancer ) . Symptomatic brain metastasis . Patients incapacitated , largely wholly bedridden confine wheelchair , little ability selfcare . Current sign symptom severe , progressive uncontrolled renal , hepatic , hematologic , endocrine , pulmonary , cardiac , neurological cerebral disease . Documented human immunodeficiency virus ( HIV ) infection . Any condition ( medical , social , psychological ) would prevent adequate followup .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>